TrialJournal for immunotherapy of cancer2018

Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer.

Jason M Redman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.